Density expression of the CD20 antigen on population of tumor cells in patients with chronic lymphoproliferative diseases;Denzita exprese antigenu CD20 na populaci nádorových buněk u pacientů s chronickými lymfoproliferacemi B-lymfocytární řady

Casopis Lekaru Ceskych

Volumn 145, Issue 9, 2006, Pages 712-716

  Sukova V ^a,c   Klabusay, M ^a   Coupek P ^b   Brychtova Y ^a   Doubek, M ^a   Mayer, J ^a  

^a UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^b CZECH GEOLOGICAL SURVEY   (Czech Republic)

^c Český Geologický Ústav ^*  (Czech Republic)

Author keywords

CD20; Chronic lymphocytic leukemia; Density; Flow cytometry; Mantle cell lymphoma; Rituximab; Small cell lymphocytic lymphoma

Indexed keywords

CD20 ANTIGEN; RITUXIMAB;

ARTICLE; BLOOD DONOR; CELL DENSITY; CELL POPULATION; CHRONIC DISEASE; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LYMPHOCYTOMA; LYMPHOPROLIFERATIVE DISEASE; MANTLE CELL LYMPHOMA; TUMOR CELL;

EID: 33749131699     PISSN: 00087335     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Mayer, J., Doubek, M., Brychtová, Y. et al.: Využití rituximabu v léčbě chronické lymfatické leukémie. Klinická onkologie, 2003, 16, s. 179-183.
2. Tedder, T. F., Engel, P.: CD20: a regulator of cell-cycle progression of B lymphocytes. Immunol. Today, 1994, 15, s. 450-454.
3. Clark, E.A., Shu, G.: Activation of human B cell proliferation through surface Bp35 (CD20) polypeptides or immunoglobulin receptors. J. Immunol., 1987, 138, s. 720-725.
4. Spits, H., Blom, B., Jaleco A.C. et al.: Early stages in the development of human T, natural killer and thymic dendritic cells. Immunol. Rev., 1998, 165, s. 75-86.
5. Hultin, L., Hausner, M., Hultin, P. et al.: CD20 (pan-B cell) antigen is expressed at a low level on a subpopulation of human T lymphocytes. Cytometry, 1993, 14, s. 196-204.
6. Algino, K. M., Thomason, R. W., King, D. E. et al.: CD20 (pan-B cell antigen) expression on bone marrow-derived T cells. Am. J. Clin. Pathol., 1996, 106, s. 78-81.
7. Tamayose, K., Sato, N., Ando, J. et al.: CD3-negative, CD20-positive T-cell prolymphocytic leukemia: case report and review of the literature. Am. J. Hematol., 2002, 71, s. 331-335.
8. Warzynski, M. J., Graham, D. M., Axtell, R. A. et al.: Low level CD20 expression on T cell malignancies. Cytometry, 1994, 18, s. 88-92.
9. Yasukawa, M., Arai, J., Kakimoto, M. et al.: CD20-positive adult T-cell leukemia. Am. J. Hematol., 2001, 66, s. 39-41.
10. Takami, A., Saito, M., Nakao, S. et al.: CD20-positive T-cell chronic lymphocytic leukemia. Br. J. Haematol., 1998, 102, s. 1327-1329.
11. Huh, Y. O., Keating, M. J., Saffer, H. L. et al.: Higher levels of surface CD20 expression on circulating lymphocytes compared with bone marrow and lymph nodes in B-cell chronic lymphocytic leukemia. Am. J. Clin. Pathol., 2001, 116, s. 437-443.
12. Venugopal, P., Sivaraman, S., Huang, X. K. et al.: Effects of cytokines on CD20 antigen expression on tumor cells from patients with chronic lymphocytic leukemia. Leuk. Res., 2000, 24, s. 411-415.
13. Anderson, D. R., Grillo-Lopez, A., Varns, C. et al.: Targeted anti-cancer therapy using rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin's B-cell lymphoma. Biochem. Soc. Trans., 1997, 25, s. 705-708.
14. McLaughlin, P., Grillo-Lopez, A. J., Link, B. K. et al.: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J. Clin. Oncol., 1998, 16, s. 2825-2833.
15. Masucci, G., Lindemalm, C., Frödin, J. E. et al.: Effect of human blood mononuclear cell populations in antibody dependent cellular cytotoxicity (ADCC) using two murine (C017-1A and Br55-2) and one chimeric (17-1A) monoclonal antibodies against a human colorectal carcinoma cell line (SW948). Hybridoma, 1988, 7, s. 429-440.
16. Reff, M. E., Carner, K., Chambers, K. S. et al.: Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood, 1994, 83, s. 435-445.
17. Demidem, A., Lam, T., Alas, S. et al: Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother. Radiopharm., 1997, 12, s. 177-185.
18. Golay, J., Lazzari, M., Facchinetti, V. et al.: CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59. Blood, 2001, 98, s. 3383-3389.
19. Bellosillo, B., Villamor, N., Lopez-Guillermo, A. et al.: Complement-mediated cell death induced by rituximab in B-cell lymphoproliferative disorders is mediated in vitro by a caspase-independent mechanism involving the generation of reactive oxygen species. Blood, 2001, 98, s. 2771-2777.
20. Foran, J. M., Cunningham, D., Coiffier, B. et al.: Treatment of mantle-cell lymphoma with rituximab (chimeric monoclonal anti-CD20 antibody): analysis of factors associated with response. Ann. Oncol., 2000, 11, s. 117-121.
21. Hagberg, H., Lundholm, L.: Rituximab, a chimaeric anti-CD20 monoclonal antibody, in the treatment of hairy cell leukaemia. Br. J. Haematol., 2001, 115, s. 609-611.
22. Davis, T. A., Grillo-Lopez, A. J., White, C. A. et al.: Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. J. Clin. Oncol., 2000, 18, s. 3135 až 3143.
23. Maloney, D. G., Grillo-Lopez, A. J., Bodkin, D. J. et al.: IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J. Clin. Oncol., 1997, 15, s. 3266-3274.
24. van der Kolk, L. E., Grillo-Lopez, A. J., Baars, J. W. et al.: Complement activation plays a key role in the side-effects of rituximab treatment. Br. J. Haematol., 2001, 115, s. 807-811.
25. Dignum, H. M., Summerfield, G. P., Proctor, S. J. et al.: Quantification of CD38 expression in B-cell chronic lymphocytic leukemia (B-CLL): a comparison between antibody binding capacity (ABC) and relative median fluorescence (RMF). Leuk. Lymphoma., 2004, 45, s. 1167-1173.
26. Henderson, L. O., Marti, G. E., Gaigalas, A. et al: Terminology and nomenclature for standardization in quantitative fluorescence cytometry. Cytometry, 1998, 33, s. 97-105.
27. Witzig, T. E., Li, C. Y., Tefferi, A., Katzmann, J. A.: Measurement of the intensity of cell surface antigen expression in B-cell chronic lymphocytic leukemia. Am. J. Clin. Pathol., 1994, 101, s. 312-317.
28. Almasri, N. M., Duque, R. E., Iturraspe J. et al.: Reduced expression of CD20 antigen as a characteristic marker for chronic lymphocytic leukemia. Am. J. Hematol., 1992, 40, s. 259-263.
29. Höffkes, H. G., Schmidtke, G., Schmucker, U. et al.: Lymphocyte gating of peripheral blood in patients with leukemic low-grade non-Hodgkin's lymphoma by multiparametric flow cytometry. Eur. J. Med. Res., 1996, 1, s. 215-222.
30. Babušíková, O., Tomová, A., Kusenda, J., Gyárfáš, J.: Flow cytometry of peripheral blood and bone marrow cells from patients with hairy cell leukemia: phenotype of hairy cells, lymphocyte subsets and detection of minimal residual disease after treatment. Neoplasma, 2001, 48, s. 350-357.
31. Tefferi, A., Bartholmai, B. J., Witzig, T. E. et al.: Heterogeneity and clinical relevance of the intensity of CD20 and immunoglobulin light-chain expression in B-cell chronic lymphocytic leukemia. Am. J. Clin. Pathol., 1996, 106, s. 457-461.
32. D'Arena, G., Musto, P., Cascavilla, N. et al.: Quantitative flow cytometry for the differential diagnosis of leukemic B-cell chronic lymphoproliferative disorders. Am. J. Hematol., 2000, 64, s. 275-281.
33. Ginaldi, L., de Martinis, M., Matutes, E. et al.: Levels of expression of CD19 and CD20 in chronic B cell leukaemias. J. Clin. Pathol., 1998, 51, s. 364-369.
34. Rossmann, E. D., Lundin, J., Lenkei, R. et al.: Variability in B-cell antigen expression: implications for the treatment ofB-cell lymphomas and leukemias with monoclonal antibodies. Hematol. J., 2001, 2, s. 300-306.